BIONTX

Building a Robust Life Science Ecosystem:

The Bridge Between Research, Clinical Trials & Manufacturing



Eric Danielson, AICP
Managing Director, Real Estate Development
NexPoint

Eric Danielson is Managing Director, Real Estate Development at NexPoint, a multibillion-dollar real estate and investment firm based in Dallas. At NexPoint, Eric is responsible for the firm's real estate development activities, including the Texas Research Quarter project, an integrated life sciences campus planned at the former EDS headquarters in Plano.

For the entirety of his career, Eric has been part of the real estate development industry, specifically focused on the life sciences. He's worked with a range of organizations committed to scientific discovery and lifesaving cures, including higher education research institutions, human health drug makers, federal research agencies, animal health product manufacturers, clinical research organizations, and health care providers.

Eric's background in the real estate development process started when he ran the economic development program for the City of Lenexa, Kansas. During that time, he was responsible for the growth of over $400M in capital investment and the creation of over 2,000 jobs. He also contributed to the legislation of the Kansas Economic Growth act, which created the Kansas Bioscience Authority and subsequent inducements for the biosciences.

As a certified planner, Eric has worked with architectural, engineering, and construction companies helping create the built environment for the life science industry. From laboratory planning to master planning for regulated good manufacturing practices (GMP) facilities, he has helped deliver award-winning projects for a range of clients operating across the industry.

Eric and his wife Allison are keeping up with their very active three children. He's actively involved in their extracurriculars and supports several community organizations with his time. When not working or with his family you can find him courtside in Allen Fieldhouse as the Public Address Announcer for the University of Kansas men's basketball program.



David Gerber, MD
Professor of Internal Medicine & Clinical Cancer Research
UT Southwestern Medical Center

David Gerber, M.D. is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Hematology/Oncology. He serves as Associate Director of Clinical Research for Simmons Cancer Center.

Originally from Chicago, Dr. Gerber holds a bachelor's degree in history from Yale University in New Haven, Connecticut, where he graduated cum laude. He earned his medical degree at Cornell University Medical College in New York, and completed his internship and residency in internal medicine at UT Southwestern, where he served as Chief Resident. He then received advanced training through a fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore.

Board certified in internal medicine and medical oncology, Dr. Gerber joined the UT Southwestern faculty in 2007. Dr. Gerber is active in research related to lung cancer, including clinical trials. His research has generated more than 250 publications that he has authored or co-authored, including articles and book chapters. His studies have contributed to invitations to lecture both nationally and internationally. He serves on several committees at UT Southwestern. Beyond the institution, he serves as Chair of the Clinical Trials Advisory Committee for the Cancer Prevention and Research Institute of Texas (CPRIT) and is a member of the National Comprehensive Cancer Network (NCCN) Oncology Research Program Investigator Steering Committee.

Alex Baldridge
Senior Director, Business Development
Caidya

Alex Baldridge is a seasoned professional in business development and operational delivery, currently serves as the Senior Director of Business Development at Caidya, a multi-therapeutic, mid-sized CRO focused on emerging biotech partnerships. With over 15 years of experience in clinical research, Alex is equipped with a deep understanding of business strategy, operations, and leadership.

At Caidya, he is at the forefront of driving business growth and innovation. His role involves leveraging technology to enhance business processes, which has significantly contributed to the company's success in the competitive market.



Brian O'Mara, MS
Vice President, Process Sciences
Scorpius BioManufacturing

Brian O'Mara has more than 20 years of industrial biotechnology experience in downstream process development of early- and late-stage protein therapeutics from mammalian and microbial expression systems. He also has extensive experience in the development and scale-up of protein conjugates, including antibody-drug conjugates (ADCs), bi-specifics, and PEGylated molecules, as well as experience in technology transfer, CDMO management, process characterization, preparation and oversight of PPQ campaigns, and associated CMC regulatory filings.

Prior to joining Scorpius BioManufacturing, he was the Director of Downstream Process Development at Ambrx, a clinical stage biopharmaceutical company recently acquired by Johnson & Johnson, and was a Senior Research Scientist II at Bristol-Myers Squibb. Brian earned a BS in Biology from Binghamton University and an MS in Chemistry from Lehigh University.

Khandan Baradaran, PhD
Senior Vice President, Regulatory & Quality
Nanoscope Therapeutics

Dr. Baradaran brings nearly two decades of extensive experience in manufacturing and regulatory review of gene therapy products, including regulatory Chemistry, Manufacturing, and Controls (CMC) experience.

Dr. Baradaran was most recently Vice President of Regulatory CMC at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company involved in the research and development of novel products for the treatment of rare and ultra-rare genetic diseases. Previously, Dr. Baradaran was Vice President and Head of Quality at Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases.

Prior to this, she held CMC and Regulatory positions at Biogen, Novartis, and Dyax. She holds a PhD in Virology from Harvard University and a BA in Molecular Biology from Wellesley College.